L2 Consulting works with an international client base of life science industries in finance, business planning, M+A, program design, executional oversight and interim management. Scientifically, L2 has contributed to over 300 new drug clinical trial applications (preclinical), has raised over U$200m in new funding and has been pivotal in closing 6 mid-sized M&A’s in the industry (including execution of full due diligence) with deal values of up to US$50m. L2’s team of Associate Partners encompasses senior level expertise in clinical, preclinical, bioanalytical immunological, finance and business/corporate development.
As an Associate Partner in L2 Consulting, Dr. Carol Meschter is an ACVP board certified veterinary pathologist with 30 years of experience evaluating tissues for both GLP IND enabling studies, peer review, and a wide variety of research models as well as immunohistochemistry. Dr. Meschter is highly skilled in the evaluation preclinical histopathology and immunohistochemistry working companies ranging from small virtual groups to the pharma giants. She takes a close scientific interest in all of her clients and their projects.
The majority of GLP histopathology studies Dr. Meschter has conducted have been parts of successful IND submissions to the FDA. High quality reports and photomicroscopy are part of any project and for GLP studies, a validated computer data acquisition system (StarTox, Druquest, Inc.), is used to produce the FDA required data tables for reports. Her pathology office offers complete set of SOPs, Master Schedule, QAU, specimen security, and other appropriate GLP documentation that is required to support GLP pathology studies.
Dr. Meschter has over 100 peer reviewed pathology related publications and was the Society of Toxicologic Pathologists winner of the Outstanding Young Investigator’s Award. She achieved her PhD at the College of Veterinary Medicine, Cornell University, Ithaca, NY, She was the Director of Laboratory Medicine at the American Health Foundation in Valhalla, NY, a pathologist in the Department of Investigative Toxicology at Hoffmann LaRoche, Nutley NJ. She founded Comparative Biosciences in Sunnyvale, CA in 1996 and grew the company steadily until 2020, when it was acquired by Genesis Biosystems, Princeton NJ.
Carol Meschter DVM, PhD, DACVP